Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME76AP)

• Drug Name: Bis(olanzapine) pamoate monohydrate Drug Info
• Synonyms: Bis[2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine] 4,4'-methylenebis(3-hydroxynaphthalen-2-carboxylic acid) salt monohydrate

Indication

Disease Entry	ICD 11	Status	REF
Psychotic disorder	6A20-6A25	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DME76AP

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[2]
Haloperidol	DM96SE0	Delirium		Approved	[3]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[4]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[5]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[6]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[7]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[8]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[9]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[10]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[11]

Drug(s) Targeting 5-HT 2 receptor (5HT2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mianserin	DMVKA4O	Depression	6A70-6A7Z	Approved	[12]
Cyclobenzaprine	DM1YBRM	Depression	6A70-6A7Z	Approved	[13]
Perospirone	DMVHJLX	Psychotic disorder	6A20-6A25	Approved	[14]
Ketanserin	DMVLMW6	Hypertension	BA00-BA04	Approved	[15]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[16]
Nexopamil	DML5S71	Hypertension	BA00-BA04	Phase 2	[17]
TGWOOAA	DMI57ZA	Generalized anxiety disorder	6B00	Phase 2	[18]
TGOF02N	DMQ6ANE	Schizophrenia	6A20	Phase 2	[19]
AMAP-102	DM7CD8Z	Arthritis	FA20	Phase 1	[20]
Heterocyclic-tetracyclic tetrahydrofuran derivative 1	DMNJVR6	N. A.	N. A.	Patented	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2 receptor (5HT2R)	TTYSN63	NOUNIPROTAC	Modulator	[1]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Modulator	[1]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [3] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [4] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [5] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [6] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [8] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [9] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [10] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [11] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [12] 5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6.
• [13] Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92.
• [14] Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8.
• [15] Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
• [18] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [19] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [20] Clinical pipeline report, company report or official report of Anamar.
• [21] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.